SIS
LGND icon

Sound Income Strategies’s Ligand Pharmaceuticals LGND Stock Holding History

Sound Income Strategies’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-98
Closed -$19.6K – 1556
2026
Q1 		$19.6K Buy
98
+41
+72% +$8.11K ﹤0.01% 1192
2025
Q4 		$11K Buy
+57
New +$11K ﹤0.01% 1417

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sound Income Strategies's LGND Position: Q2 2026 in Review

Sound Income Strategies sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 98 shares — an estimated $19.6K sold.

Sound Income Strategies first reported a position in LGND in Q4 2025 and held it in 2 quarters. The position peaked at $19.6K in Q1 2026. 156 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Sound Income Strategies reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 98 Ligand Pharmaceuticals shares in Q2 2026, an estimated $19.6K.
  • Sound Income Strategies first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Ligand Pharmaceuticals position peaked at $19.6K in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.